John J. Miller

Addressing the importance of safe treatments for PTSD, Dr John Miller discusses adverse effect management practices and the role of REMS protocols.

The Psychiatric Times editor-in-chief shares perspectives on how a novel treatment, MDMA-assisted therapy, can potentially change the treatment landscape and improve patients’ lives.

John J. Miller, MD, discusses the risks of untreated PTSD and the importance of implementing more therapeutic tools into treatment paradigms.

John J. Miller, MD, discusses how the diagnosis and treatment of posttraumatic stress disorder (PTSD) has evolved over time.

SPECIAL REPORT: ADVANCES IN PSYCHIATRY We are at the halfway point of the year, and psychiatry continues to be exciting, with advances in the field, potential new treatments on the horizon, and great insights from leaders in the field. This special report helps to keep that conversation and momentum going by covering highlights from the 2024 American Psychiatric Association’s Annual Meeting held in May in New York, New York. Psychiatric Times’ coverage included summaries of presentations, int…

John J. Miller, MD, Editor-in-Chief of Psychiatric Times, puts in perspective the US Food and Drug Administration Psychopharmacologic Drugs Advisory Committee’s decision on MDMA for the treatment of posttraumatic stress disorder (PTSD). While they voted against recommending FDA approval for MDMA, the picture is more complicated, shared Miller. The committee, though valid in its concerns, does not have final say over this decision. The FDA will issue its verdict on Lykos’ application on August…

Without doubt, the STAR*D trial is one of the most important foundational studies in psychiatry to guide the treatment of unipolar major depression. Despite the significant evolution of pharmacotherapies that have joined our antidepressant armamentarium since STAR*D’s publication in 2006, the broader findings of percent response and remission of patients with depression at each of the 4 steps remain as relevant to us today as they were 18 years ago. For that reason, I wrote the December 2023…

In the treatment of major depressive disorder (MDD), the acronym STAR*D stands out as a beacon guiding treatment decisions since 2006 when a series of publications reported the results from this massive, $35 million National Institute of Mental Health (NIMH)–funded research study. Recently, a provocative and well-researched publication in the BMJ reanalyzed the original raw data obtained from the NIMH and challenged the conclusions of the STAR*D publications. The Sequenced Treatment Alternat…

John J. Miller, MD, Editor in Chief of Psychiatric Times, will present on the 14 different types of dementia on Saturday October 21st at 1:55PM EST. You can attend this session by registering here. Dr Miller is Medical Director, Brain Health, Exeter, New Hampshire; Editor in Chief, Psychiatric Times®; Staff Psychiatrist, Seacoast Mental Health Center, Exeter; Consulting Psychiatrist, Exeter Hospital, Exeter; Consulting Psychiatrist, Insight Meditation Society, Barre, Massachusetts.

John J. Miller, Editor in Chief of Psychiatric Times, will present in the first hour of our conference, which focuses on schizophrenia. You can join the conversation here. Dr Miller is Medical Director, Brain Health, Exeter, New Hampshire; Editor in Chief, Psychiatric Times®; Staff Psychiatrist, Seacoast Mental Health Center, Exeter; Consulting Psychiatrist, Exeter Hospital, Exeter; Consulting Psychiatrist, Insight Meditation Society, Barre, Massachusetts.